The American Journal of Managed Care14h
Fexagratinib in MS Shows Promise for Human Use
Fexagratinib targets FGF, CSF, and VEGF pathways, showing potential in MS treatment by reducing inflammation and promoting ...
The American Journal of Managed Care8h
Lower Pharmacy Costs Give Ruxolitinib Edge for Patients With MF and Anemia
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
The American Journal of Managed Care19h
Fixed-Duration 1L CLL Treatment Reduces Long-Term Costs in the Real World
The venetoclax-based regimen was associated with an approximate $8000 decrease in costs compared with the continuous Bruton ...